Neurotherapeutics

, Volume 7, Issue 4, pp 413–423

Astrocytes and therapeutics for Parkinson’s disease

Review Article

Summary

Astrocytes play direct, active, and critical roles in mediating neuronal survival and function in various neurodegenerative disorders. This role of astrocytes is well illustrated in amyotrophic lateral sclerosis (ALS), in which the removal of glutamate from the extracellular space by astrocytes confers neuroprotection, whereas astrocytic release of soluble toxic molecules promotes neurodegeneration. In recent years, this context-dependent dual role of astrocytes has also been documented in experimental models of Parkinson’s disease. The present review addresses these studies and some potential mechanisms by which astrocytes may influence the neurodegenerative processes in Parkinson’s disease, and in particular examines how astrocytes confer neuroprotection either through the removal of toxic molecules from the extracellular space or through the release of trophic factors and antioxidant molecules. In contrast, under pathological conditions, astrocytes release proinflammatory cytokines and other toxic molecules that are detrimental to dopaminergic neurons. These emerging roles of astrocytes in the pathogenesis of Parkinson’s disease constitute an exciting development with promising novel therapeutic targets.

Key Words

Parkinson’s disease astrocytes neurodegeneration dopamine glial-neuronal interactions neurodegenerative diseases 

References

  1. 1.
    Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003;39: 889–909.PubMedGoogle Scholar
  2. 2.
    Lees AJ, Hardy J, Revesz T. Parkinson’s disease [Erratum in: Lancet 2009;374:684]. Lancet 2009;373: 2055–2066.PubMedGoogle Scholar
  3. 3.
    Krusz JC, Koller WC, Ziegler DK. Historical review: abnormal movements associated with epidemic encephalitis lethargica. Mov Disord 1987;2: 137–141.PubMedGoogle Scholar
  4. 4.
    Calne DB, Lees AJ. Late progression of post-encephalitic Parkinson’s syndrome. Can J Neurol Sci 1988;15: 135–138.PubMedGoogle Scholar
  5. 5.
    Langston JW, Ballard P, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219: 979–980.PubMedGoogle Scholar
  6. 6.
    Olanow CW. Manganese-induced parkinsonism and Parkinson’s disease. Ann N Y Acad Sci 2004;1012: 209–223.PubMedGoogle Scholar
  7. 7.
    Tanner CM. Epidemiology of Parkinson’s disease. Neurol Clin 1992;10: 317–329.PubMedGoogle Scholar
  8. 8.
    Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology 1997;48: 1583–1588.PubMedGoogle Scholar
  9. 9.
    Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson’s disease: a case-control study of occupational and environmental risk factors. Am J Ind Med 1990;17: 349–355.PubMedGoogle Scholar
  10. 10.
    Ritz BR, Manthripragada AD, Costello S, et al. Dopamine transporter genetic variants and pesticides in Parkinson’s disease. Environ Health Perspect 2009;117: 964–969.PubMedGoogle Scholar
  11. 11.
    Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. Well-water consumption and Parkinson’s disease in rural California. Environ Health Perspect 2009;117: 1912–1918.PubMedGoogle Scholar
  12. 12.
    Gupta A, Dawson VL, Dawson TM. What causes cell death in Parkinson’s disease? Ann Neurol 2008;64 (Suppl 2): S3-S15.PubMedGoogle Scholar
  13. 13.
    Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. The genetics of Parkinson’s syndromes: a critical review. Curr Opin Genet Dev 2009;19: 254–265.PubMedGoogle Scholar
  14. 14.
    Przedborski S. Neuroinflammation and Parkinson’s disease. Handb Clin Neurol 2007;83: 535–551.PubMedGoogle Scholar
  15. 15.
    Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 2009;8: 382–397.PubMedGoogle Scholar
  16. 16.
    Sherwood CC, Stimpson CD, Raghanti MA, et al. Evolution of increased glia-neuron ratios in the human frontal cortex. Proc Natl Acad Sci U S A 2006;103: 13606–13611.PubMedGoogle Scholar
  17. 17.
    Mena MA, Garcia de Yébenes J. Glial cells as players in parkinsonism: the “good,” the “bad,” and the “mysterious” glia. Neuroscientist 2008;14: 544–560.PubMedGoogle Scholar
  18. 18.
    Heneka MT, Rodríguez JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev 2010;63: 189–211.PubMedGoogle Scholar
  19. 19.
    Richter C. Reactive oxygen and DNA damage in mitochondria. Mutat Res 1992;275: 249–255.PubMedGoogle Scholar
  20. 20.
    Beal MF. Oxidatively modified proteins in aging and disease. Free Radie Biol Med 2002;32: 797–803.Google Scholar
  21. 21.
    Malkus KA, Tsika E, Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson’s disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 2009;4: 24.PubMedGoogle Scholar
  22. 22.
    Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009;390: 191–214.PubMedGoogle Scholar
  23. 23.
    Rice ME, Russo-Menna I. Differential compartmentalization of brain ascorbate and glutathione between neurons and glia. Neuroscience 1998;82: 1213–1223.PubMedGoogle Scholar
  24. 24.
    Bolanos JP, Heales SJ, Land JM, Clark JB. Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture. J Neurochem 1995;64: 1965–1972.PubMedGoogle Scholar
  25. 25.
    Gegg ME, Beltran B, Salas-Pino S, et al. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration? J Neurochem 2003;86: 228–237.PubMedGoogle Scholar
  26. 26.
    Hirrlinger J, Schulz JB, Dringen R. Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J Neurosci Res 2002;69: 318–326.PubMedGoogle Scholar
  27. 27.
    Hirrlinger J, König J, Dringen R. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J Neurochem 2002;82: 716–719.PubMedGoogle Scholar
  28. 28.
    Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson’s disease: is this the elephant in the room? Biomed Pharmacother 2008;62: 236–249.PubMedGoogle Scholar
  29. 29.
    Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36: 348–355.PubMedGoogle Scholar
  30. 30.
    Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J Neural Transm 1997;104: 661–677.PubMedGoogle Scholar
  31. 31.
    Solano RM, Casarejos MJ, Menéndez-Cuervo J, et al. Glial dysfunction in parkin null mice: effects of aging. J Neurosci 2008;28: 598–611.PubMedGoogle Scholar
  32. 32.
    Toffa S, Kunikowska GM, Zeng BY, Jenner P, Marsden CD. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm 1997;104: 67–75.PubMedGoogle Scholar
  33. 33.
    Zeevalk GD, Bernard LP, Sinha C, Ehrhart J, Nicklas WJ. Excitotoxicity and oxidative stress during inhibition of energy metabolism. Dev Neurosci 1998;20: 444–453.PubMedGoogle Scholar
  34. 34.
    Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson’s disease. Proc Natl Acad Sci U S A 2005;102: 8024–8029.PubMedGoogle Scholar
  35. 35.
    Trinh K, Moore K, Wes PD, et al. Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson’s disease. J Neurosci 2008;28: 465–472.PubMedGoogle Scholar
  36. 36.
    Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord 2009;24: 979–983.PubMedGoogle Scholar
  37. 37.
    Cornford EM, Braun LD, Crane PD, Oldendorf WH. Blood-brain barrier restriction of peptides and the low uptake of enkephalins. Endocrinology 1978;103: 1297–1303.PubMedGoogle Scholar
  38. 38.
    Kannan R, Kuhlenkamp JE, Jeandidier E, Trinh H, Ookhtens M, Kaplowitz N. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 1990;85: 2009–2013.PubMedGoogle Scholar
  39. 39.
    McLellan LI, Lewis AD, Hall DJ, Ansell JD, Wolf CR. Uptake and distribution of N-acetylcysteine, in mice: tissue-specific effects on glutathione concentrations. Carcinogenesis 1995: 16: 2099–2106.PubMedGoogle Scholar
  40. 40.
    Itoh K, Chiba T, Takahashi S, et al. An Nrf2/smail Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236: 313–322.PubMedGoogle Scholar
  41. 41.
    Vargas MR, Johnson JA. The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev Mol Med 2009;11: e17.PubMedGoogle Scholar
  42. 42.
    Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009;284: 13291–13295.PubMedGoogle Scholar
  43. 43.
    Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003;278: 12029–12038.PubMedGoogle Scholar
  44. 44.
    Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 2004;24: 1101–1112.PubMedGoogle Scholar
  45. 45.
    Shih AY, Johnson DA, Wong G, et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 2003;23: 3394–3406.PubMedGoogle Scholar
  46. 46.
    Chen PC, Vargas MR, Pani AK, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 2009;106: 2933–2938.PubMedGoogle Scholar
  47. 47.
    Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. DJ-1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 2006;103: 15091–15096.PubMedGoogle Scholar
  48. 48.
    Hague S, Rogaeva E, Hernandez D, et al. Early-onset Parkinson’s disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 2003;54: 271–274.PubMedGoogle Scholar
  49. 49.
    Bonifati V, Rizzu P, Van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299: 256–259.PubMedGoogle Scholar
  50. 50.
    Bandopadhyay R, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain 2004;127: 420–430.PubMedGoogle Scholar
  51. 51.
    Waak J, Weber SS, Waldenmaier A, et al. Regulation of astrocyte inflammatory responses by the Parkinson’s disease-associated gene DJ-1. FASEB J 2009;23: 2478–2489.PubMedGoogle Scholar
  52. 52.
    Grothe C, Timmer M. The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system. Brain Res Rev 2007;54: 80–91.PubMedGoogle Scholar
  53. 53.
    Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260: 1130–1132.PubMedGoogle Scholar
  54. 54.
    Saavedra A, Baltazar G, Santos P, Carvalho CM, Duarte EP. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol Dis 2006;23: 533–542.PubMedGoogle Scholar
  55. 55.
    Petrova PS, Raibekas A, Pevsner J, et al. Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Prog Brain Res 2004;146: 168–183.PubMedGoogle Scholar
  56. 56.
    Deierborg T, Soulet D, Roybon L, Hall V, Brundin P. Emerging restorative treatments for Parkinson’s disease. Prog Neurobiol 2008;85: 407–432.PubMedGoogle Scholar
  57. 57.
    Nutt JG, Burchiel KJ, Comelia CL, et al.; ICV GDNF Study Group. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60: 69–73.PubMedGoogle Scholar
  58. 58.
    Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease [Erratum in: Ann Neurol 2006;60:747]. Ann Neurol 2006;59: 459–466.PubMedGoogle Scholar
  59. 59.
    Salvatore MF, Ai Y, Fischer B, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006;202: 497–505.PubMedGoogle Scholar
  60. 60.
    Voutilainen MH, Back S, Pörsti E, et al. Mesencephalic astrocytederived neurotrophic factor is neurorestorative in rat model of Parkinson’s disease. J Neurosci 2009;29: 9651–9659.PubMedGoogle Scholar
  61. 61.
    Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25: 239–252.PubMedGoogle Scholar
  62. 62.
    Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the a-synuclein gene identified in families with Parkinson’s disease. Science 1997;276: 2045–2047.PubMedGoogle Scholar
  63. 63.
    Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat Genet 1998;18: 107–108.Google Scholar
  64. 64.
    Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of α-synucleiu causes Parkinson and Lewy body dementia. Ann Neurol 2004;55: 164–173.PubMedGoogle Scholar
  65. 65.
    Singleton AB, Fairer M, Johnson J, et al. α-Synuclein locus triplication causes Parkinson’s disease. Science 2003;302: 841.PubMedGoogle Scholar
  66. 66.
    Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr. NACP, a protein implicated in Alzheimer’s disease, and learning, is natively unfolded. Biochemistry 1996;35: 13709–13715.PubMedGoogle Scholar
  67. 67.
    Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006: 116: 1744–1754.PubMedGoogle Scholar
  68. 68.
    Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 2008;14: 501–503.PubMedGoogle Scholar
  69. 69.
    Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 2008;14: 504–506.PubMedGoogle Scholar
  70. 70.
    Mendez I, Viñuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson’s disease, survive without pathology for 14 years. Nat Med 2008;14: 507–509.PubMedGoogle Scholar
  71. 71.
    Brandin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson’s disease pathology spread. Nat Rev Neurosci 2008;9: 741–745.Google Scholar
  72. 72.
    Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein [Erratum in: Proc Natl Acad Sci U S A 2009; 106: 17606]. Proc Natl Acad Sci U S A 2009;106: 13010–13015.PubMedGoogle Scholar
  73. 73.
    Lee HJ, Suk JE, Patrick C, et al. Direct transfer of a-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010;285: 9262–9272.PubMedGoogle Scholar
  74. 74.
    Brundin P, Li JY, Holtou JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson’s disease pathology spread. Nat Rev Neurosci 2008;9: 741–745.PubMedGoogle Scholar
  75. 75.
    Olanow CW, Prusiner SB. Is Parkinson’s disease a prion disorder? Proc Natl Acad Sci U S A 2009;106: 12571–12572.PubMedGoogle Scholar
  76. 76.
    Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson’s disease? Neurobiol Dis 2007;25: 134–149.PubMedGoogle Scholar
  77. 77.
    Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004;10: 719–726.PubMedGoogle Scholar
  78. 78.
    Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003;9: 453–457.PubMedGoogle Scholar
  79. 79.
    Langsten JW, Irwin I. MPTP: current concepts and controversies. Clin Neuropharmacol 1986;9: 485–507.Google Scholar
  80. 80.
    Heikkila RE, Sieber BA, Manzino L, Sonsalla PK. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 1989;10: 171–183.PubMedGoogle Scholar
  81. 81.
    Christine CW, Langston JW, Turner RS, Starr PA. The neuro-physiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. J Neurosurg 2009;110: 234–238.PubMedGoogle Scholar
  82. 82.
    Cui M, Aras R, Christian WV, et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 2009;106: 8043–8048.PubMedGoogle Scholar
  83. 83.
    Javitch JA, D’Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explain selective toxicity. Proc Natl Acad Sci USA 1985;82: 2173–2177.PubMedGoogle Scholar
  84. 84.
    Mayer RA, Kindt MV, Heikkila RE. Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylmine transport. J Neurochem 1986;47: 1073–1079.PubMedGoogle Scholar
  85. 85.
    Namura I, Douillet P, Sun CJ, Pert A, Cohen RM, Chiueh CC. MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons. Eur J Pharmacol 1987;136: 31–37.PubMedGoogle Scholar
  86. 86.
    McNaught KS, Carrupt PA, Altomare C, et al. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson’s disease. Biochem Pharmacol 1998;56: 921–933.PubMedGoogle Scholar
  87. 87.
    Mahy N, Andrés N, Andrade C, Saura J. Age-related changes of MAO-A and -B distribution in human and mouse brain. Neurobiology (Bp) 2000;8: 47–54.Google Scholar
  88. 88.
    Fowler CJ, Wiberg A, Orelaud L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980;49: 1–20.PubMedGoogle Scholar
  89. 89.
    Mandel S, Grunblatt E, Riederer P, Youdim MB. Genes and oxidative stress in parkinsonism: cDNA microarray studies. Adv Neurol 2003: 91: 123–132.PubMedGoogle Scholar
  90. 90.
    Mallajosyula JK, Kaur D, Chinta SJ, et al. MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS One 2008;3: e1616.PubMedGoogle Scholar
  91. 91.
    Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996;379: 733–736.PubMedGoogle Scholar
  92. 92.
    Saccone NL, Rice JP, Rochberg N, et al. Genome screen for platelet monoamine oxidase (MAO) activity. Am J Med Genet 1999: 88: 517–521.PubMedGoogle Scholar
  93. 93.
    Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328: 176–183.Google Scholar
  94. 94.
    Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51: 604–612.PubMedGoogle Scholar
  95. 95.
    Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Ann Neurol 1998;43: 318–325.Google Scholar
  96. 96.
    Olanow CW. Rationale for considering that propargylamines might be neuroprotective in Parkinson’s disease. Neurology 2006;66 (Suppl 4): S69-S79.PubMedGoogle Scholar
  97. 97.
    Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains. Acta Neuropathol 2000;99: 14–20.PubMedGoogle Scholar
  98. 98.
    Saijo K, Winner B, Carson CT, et al. A Nurrl/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009: 137: 47–59.PubMedGoogle Scholar
  99. 99.
    Kadkhodaei B, Ito T, Joodmardi E, et al. Nurrl is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci 2009: 29: 15923–15932.PubMedGoogle Scholar
  100. 100.
    Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurrl-deficient mice. Science 1997;276: 248–250.PubMedGoogle Scholar
  101. 101.
    Jankovic J, Chen S, Le WD. The role of Nurrl in the development of dopaminergic neurons and Parkinson’s disease. Prog Neurobiol 2005: 77: 128–138.PubMedGoogle Scholar
  102. 102.
    Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson disease [Erratum in: Nat Genet 2003;33: 214]. Nat Genet 2003: 33: 85–89.PubMedGoogle Scholar
  103. 103.
    Grimes DA, Han F, Panisset M, et al. Translated mutation in the Nurrl gene as a cause for Parkinson’s disease. Mov Disord 2006;21: 906–909.PubMedGoogle Scholar
  104. 104.
    Jacobsen KX, MacDonald H, Lemonde S, et al. A Nurrl point mutant, implicated in Parkinson’s disease, uncouples ERK1/2-dependent regulation of tyrosine hydroxylase transcription. Neurobiol Dis 2008;29: 117–122.PubMedGoogle Scholar
  105. 105.
    Dubois C, Hengerer B, Mattes H. Identification of a potent agonist of the orphan nuclear receptor Nurrl. ChemMedChem 2006;1: 955–958.PubMedGoogle Scholar
  106. 106.
    Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends Neurosci 2009: 32: 19–29.PubMedGoogle Scholar
  107. 107.
    Boison D, Chen JF, Fredholm BB. Adenosine signaling and function in glial cells. Cell Death Differ 2010;17: 1071–1082.PubMedGoogle Scholar
  108. 108.
    Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 1998;401: 163–186.PubMedGoogle Scholar
  109. 109.
    Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991: 57: 1062–1067.PubMedGoogle Scholar
  110. 110.
    Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci 2006;29: 647–654.PubMedGoogle Scholar
  111. 111.
    Verkhratsky A, Krishtal OA, Burnstock G. Purinoceptors on neuroglia. Mol Neurobiol 2009;39: 190–208.PubMedGoogle Scholar
  112. 112.
    Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 2001;39: 233–238.Google Scholar
  113. 113.
    Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43: 507–513.PubMedGoogle Scholar
  114. 114.
    Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson’s disease. Handb Exp Pharmacol 2009;193: 589–615.PubMedGoogle Scholar
  115. 115.
    Pinna A. Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Investig Drugs 2009;18: 1619–1631.PubMedGoogle Scholar
  116. 116.
    Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A2A antagonists, and Parkinson’s disease. Parkinsonism Relat Disord 2009;15: 406–413.PubMedGoogle Scholar
  117. 117.
    Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283: 2674–2679.PubMedGoogle Scholar
  118. 118.
    Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol 2001;50: 56–63.PubMedGoogle Scholar
  119. 119.
    Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci 2001;21: RC143.PubMedGoogle Scholar
  120. 120.
    Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease. J Neurochem 2002;80: 262–270.PubMedGoogle Scholar
  121. 121.
    Pierri M, Vaudano E, Sager T, Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005;48: 517–524.PubMedGoogle Scholar
  122. 122.
    Anderson CM, Bergher JP, Swanson RA. ATP-induced ATP release from astrocytes. J Neurochem 2004;88: 246–256.PubMedGoogle Scholar
  123. 123.
    Bowser DN, Khakh BS. Vesicular ATP is the predominant cause of intercellular calcium waves in astrocytes. J Gen Physiol 2007;129: 485–491.PubMedGoogle Scholar
  124. 124.
    Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson’s disease. Neuron 2010;66: 646–661.PubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  1. 1.Department of Neurology in the Center for Translational NeuromedicineUniversity of Rochester School of MedicineRochester

Personalised recommendations